ISPOR Europe 2025 brought together global HTA bodies, payers, industry leaders and patient organisat...
Read more2025 was a pivotal year for market access, marked by the growing convergence between scientific inno...
Read moreClinical innovation has never moved faster. Tools like single-arm designs, novel surrogates, and ada...
Read moreObjectives: EUHTA regulation has applied from the 1st January 2025 for oncology pr...
Read moreObjectives: To analyse how the mandatory EU Joint Clinical Assessment (JCA) could in...
Read moreSurrogate Endpoints in HTA Decision-Making The need to stay ahead of competitors and offset losses f...
Read moreOptimising evidence generation in trial design, while navigating regulatory and local payer requirem...
Read moreSuccessfully navigating early payer scientific advice whether through Joint Scientific Consultations...
Read moreFive success pillars — your JCA evidence-generation checklist From 12th January 2025, the Eu...
Read moreThe recent Medicines and Healthcare products Regulatory Agency (MHRA) approval of the Alzheimer’s ...
Read more